BR112014018712A8 - Derivados de morfolinila úteis como inibidores de mogat-2 - Google Patents

Derivados de morfolinila úteis como inibidores de mogat-2

Info

Publication number
BR112014018712A8
BR112014018712A8 BR112014018712A BR112014018712A BR112014018712A8 BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8 BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8
Authority
BR
Brazil
Prior art keywords
morpholinil
mogat
inhibitors
derivatives useful
compounds
Prior art date
Application number
BR112014018712A
Other languages
English (en)
Other versions
BR112014018712A2 (pt
Inventor
Rosario Gonzalez-Garcia Maria
Carmen Fernandez Maria
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48905712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014018712(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112014018712A2 publication Critical patent/BR112014018712A2/pt
Publication of BR112014018712A8 publication Critical patent/BR112014018712A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DERIVADOS DE MORFOLINILA ÚTEIS COMO INIBIDORES DE MOGAT-2. A presente invenção fornece compostos da Fórmula I ou um sal farmacêutico dos mesmos, métodos de tratamento de hipertrigliceridemia usando os compostos; e um processo para a preparação dos compostos.
BR112014018712A 2012-01-31 2013-01-24 Derivados de morfolinila úteis como inibidores de mogat-2 BR112014018712A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12382037 2012-01-31
US201261617093P 2012-03-29 2012-03-29
EP12382433 2012-11-06
PCT/US2013/022828 WO2013116065A1 (en) 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as mogat-2 inhibitors

Publications (2)

Publication Number Publication Date
BR112014018712A2 BR112014018712A2 (pt) 2017-06-20
BR112014018712A8 true BR112014018712A8 (pt) 2017-07-11

Family

ID=48905712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018712A BR112014018712A8 (pt) 2012-01-31 2013-01-24 Derivados de morfolinila úteis como inibidores de mogat-2

Country Status (24)

Country Link
US (1) US8993568B2 (pt)
EP (1) EP2809661B1 (pt)
JP (1) JP5852269B2 (pt)
KR (1) KR20140107641A (pt)
CN (1) CN104080777B (pt)
AP (1) AP2014007793A0 (pt)
AU (1) AU2013215549B2 (pt)
BR (1) BR112014018712A8 (pt)
CA (1) CA2859992A1 (pt)
CL (1) CL2014001862A1 (pt)
CO (1) CO7020914A2 (pt)
CR (1) CR20140325A (pt)
DO (1) DOP2014000177A (pt)
EA (1) EA024182B1 (pt)
ES (1) ES2571577T3 (pt)
GT (1) GT201400169A (pt)
HK (1) HK1199024A1 (pt)
IL (1) IL233542A0 (pt)
MX (1) MX2014008604A (pt)
PE (1) PE20141789A1 (pt)
PH (1) PH12014501712B1 (pt)
SG (1) SG11201404508XA (pt)
WO (1) WO2013116065A1 (pt)
ZA (1) ZA201405227B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2807147A1 (en) 2012-01-23 2014-12-03 Eli Lilly and Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
CA2859992A1 (en) 2012-01-31 2013-08-08 Eli Lilly And Company Novel morpholinyl derivatives useful as mogat-2 inhibitors
TW201343629A (zh) 2012-01-31 2013-11-01 Lilly Co Eli 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
WO2017110841A1 (ja) 2015-12-21 2017-06-29 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
TWI840489B (zh) 2019-01-11 2024-05-01 日商鹽野義製藥股份有限公司 酮衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
CA2338994A1 (en) 1998-07-31 2000-02-10 Paul Leslie Ornstein Sulfonamide derivatives
AU5233999A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Alkenyl sulphonamide derivatives
GB0408777D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
WO2008038768A1 (fr) * 2006-09-28 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
RU2010126828A (ru) * 2007-12-05 2012-01-10 Астразенека Аб (Se) Производные морфолина в качестве средств против ожирения
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2725949A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab New pyridine derivatives as leptin receptor modulator mimetics
WO2010095767A1 (en) 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
EP2807147A1 (en) 2012-01-23 2014-12-03 Eli Lilly and Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
CA2859992A1 (en) 2012-01-31 2013-08-08 Eli Lilly And Company Novel morpholinyl derivatives useful as mogat-2 inhibitors
TW201343629A (zh) 2012-01-31 2013-11-01 Lilly Co Eli 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors

Also Published As

Publication number Publication date
IL233542A0 (en) 2014-08-31
PH12014501712A1 (en) 2014-10-13
SG11201404508XA (en) 2014-10-30
AU2013215549B2 (en) 2015-09-03
US20150005305A1 (en) 2015-01-01
MX2014008604A (es) 2014-08-22
JP2015504917A (ja) 2015-02-16
BR112014018712A2 (pt) 2017-06-20
PH12014501712B1 (en) 2014-10-13
WO2013116065A1 (en) 2013-08-08
ES2571577T3 (es) 2016-05-26
CO7020914A2 (es) 2014-08-11
GT201400169A (es) 2015-08-27
CN104080777B (zh) 2015-12-09
HK1199024A1 (zh) 2015-06-19
EA201491227A1 (ru) 2015-01-30
CR20140325A (es) 2014-08-25
EP2809661A1 (en) 2014-12-10
AP2014007793A0 (en) 2014-07-31
CA2859992A1 (en) 2013-08-08
AU2013215549A1 (en) 2014-07-17
PE20141789A1 (es) 2014-11-19
EP2809661B1 (en) 2016-04-06
KR20140107641A (ko) 2014-09-04
CL2014001862A1 (es) 2014-11-14
US8993568B2 (en) 2015-03-31
DOP2014000177A (es) 2014-08-31
CN104080777A (zh) 2014-10-01
EA024182B1 (ru) 2016-08-31
ZA201405227B (en) 2016-05-25
JP5852269B2 (ja) 2016-02-03

Similar Documents

Publication Publication Date Title
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
BR112014018712A8 (pt) Derivados de morfolinila úteis como inibidores de mogat-2
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
BR112014027236A2 (pt) pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
ECSP14013211A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BR112015004547A2 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2
BR112016007396A2 (pt) derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
BR112015004029A8 (pt) processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo, e, composto
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
BR112015003201A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112015009567A2 (pt) compostos de benzil sulfonamida novos úteis como inibidores de mogat-2
BR112016013946A8 (pt) quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit
EA201590656A1 (ru) Азаиндолины
BR112015007312A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]